Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial

Pere Leyes¹*, Esteban Martínez², María Larrousse², Montserrat Cofán³, Joan Trabal⁵, Ana María Pérez-Heras³,⁴, María T Forga¹ and Emilio Ros³,⁴

Abstract

Background: The effects of ezetimibe on cholesterol metabolism in HIV-infected patients receiving boosted protease inhibitors have not been thoroughly assessed. The aim of this study was to assess cholesterol homeostasis in patients with PI associated dyslipidemia and its relationship with the response to treatment with the cholesterol-absorption inhibitor ezetimibe.

Methods: Fifteen patients with ritonavir-boosted PI-containing therapy and LDL-cholesterol > 3.36 mmol/L (>130 mg/dL) were assessed at baseline and after an 8-week course of ezetimibe 10 mg/d. Serum non-cholesterol sterols were measured at each visit as markers of cholesterol synthesis and absorption. Total-, LDL-, and HDL-cholesterol triglycerides, apolipoproteins A1 and B, high sensitivity C-reactive protein, CD4 cells and HIV-1 RNA were also measured.

Results: Ezetimibe treatment was well tolerated in all patients and resulted in significant reductions in total cholesterol (−11.4%, p = .002), LDL-cholesterol (−20.4%, p = .003), non-HDL-cholesterol (−13.4%, p = .002) and apolipoprotein B (−9.1%, p = .021). Treatment with ezetimibe was associated with decreased cholesterol absorption markers (campesterol-to-cholesterol ratio −43.0%, p = .001; sitosterol-to-cholesterol ratio −41.9%, p = .001) and increased synthesis markers (lathosterol-to-cholesterol ratio 53.2%, p = .005). Baseline absorption or synthesis markers were unrelated to the response to treatment. CD4 cell count and plasma HIV-1 RNA remained unchanged.

Conclusions: The level of cholesterol absorption or synthesis does not appear to be a major determinant of the responsiveness to ezetimibe in patients on ritonavir-boosted PI-containing therapy.

Trial registration: EudraCT: 2006-006156-36

Keywords: HIV infection, Cholesterol, Phytosterols, Ezetimibe, Protease inhibitors

Background

Abnormalities of lipid metabolism are common complications of HIV therapy, particularly with protease inhibitors (PI) [1]. Antiretroviral treatment exposure is an independent risk factor for cardiovascular disease in HIV-infected patients [2], which is particularly linked to PI exposure and relates in part to lipid alterations [3]. This risk adds to conventional risk factors, particularly smoking, which is highly prevalent among seropositive patients [4]. In addition, HIV-associated inflammation and vascular dysfunction may also lead to increased cardiovascular morbidity despite successful antiretroviral therapy (ART) [5].

Although statins are considered the drugs of choice for attaining LDL-cholesterol targets in HIV-infected patients [6], some statins may display clinically significant interactions with common antiretroviral drugs through inhibition of CYP3A metabolic pathways [7]. Furthermore, statin therapy in HIV-infected patients has a lipid-
lowering efficacy lower than expected, thus patients may require high doses or additional cholesterol-lowering agents [8]. Ezetimibe is a lipid lowering agent that reversibly inhibits intestinal cholesterol absorption without interfering with hepatic P-450 enzymes [9], thus showing a low potential for drug interactions compared with currently available statins. As PI increase cholesterol synthesis through activation of SREBP regulated pathways [10], it is unknown whether the use of a cholesterol-absorption inhibitor in HIV-infected patients treated with PI induces different changes in cholesterol metabolism than those reported in non-HIV infected dyslipidemic patients.

Small amounts of non-cholesterol sterols circulate in blood and can be used as reliable biomarkers of cholesterol metabolism [11]. Plasma cholesterol precursors such as lathosterol are markers of cholesterol synthesis and, when expressed as ratios to cholesterol, show a good correlation with synthesis rates measured by isotope kinetic techniques [12]. Plant sterols or phytosterols are absorbed in the small bowel via the same receptor involved in cholesterol absorption (NPC1L1) [13]. Therefore, plasma levels of the main phytosterols, campesterol and sitosterol, can be used as indicators of cholesterol absorption [8,14].

In general population with hypercholesterolemia, treatment with ezetimibe resulted in decreased LDL-cholesterol by −17 to −20% [15-17]. A reduction in campesterol/cholesterol and sitosterol/cholesterol ratios (−41 and −34%, respectively), and an increase in lathosterol/cholesterol ratio (+72%) has also been reported [15,17,18].

The aim of this study was to assess cholesterol homeostasis in patients with PI-associated dyslipidemia and its relationship with the response to treatment with the cholesterol-absorption inhibitor ezetimibe.

Methods

Patients

HIV-infected adults (≥18 years) receiving stable ritonavir-boosted PI-containing ART, with plasma HIV-1 RNA below 50 copies/ml at least for the previous 6 months, and presenting with plasma LDL-cholesterol levels between 3.36 and 4.91 mmol/l (130–190 mg/dL) without statin therapy were considered eligible for study. Exclusion criteria were: hypersensitivity to ezetimibe, consumption of phytosterol-enriched functional foods within one month before study entry, prior history of cardiovascular disease, secondary hypercholesterolemia, renal insufficiency (defined by a glomerular filtration rate (MDRD) <60 mL/min/1.73 m²), increased transaminase levels (defined by 5 times above the upper level of normality), concomitant treatment for hepatitis virus coinfections, diabetes mellitus, active illicit drug or alcohol abuse, AIDS-defining opportunistic infection within 3 months prior to study entry, any acute illness within one month prior to study entry, and pregnancy or breastfeeding. Criteria for patient withdrawal from the study were any changes in antiretroviral regimen during the study period, including dose changes or drug discontinuation.

The study was approved by the institutional review board of Hospital Clinic de Barcelona, and conducted according to good practice guidelines. All patients provided written informed consent before study entry.

Study design

In this open-label intervention study, participants received ezetimibe 10 mg/d during 8 weeks. At study entry, all patients received written recommendations to ensure avoidance of phytosterol supplements during the study period. Patients were scheduled for visits at baseline and week 8. At each visit 3-day food records were obtained and the nutrient composition of the diet was assessed by using Food Process-Plus software (version 8.0). Spent boxes of medication were collected to assess compliance. Anthropometric measurements were made by standard methods. Waist circumference was measured in the upright position half way between the lower subcostal margin and the iliac crest. Previous ART was recorded as time of exposure to combination ART (cART) as well as to thymidine and non-thymidine analogues (TA) Reverse Transcriptase Inhibitors (RTI), PI, and non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) families.

Laboratory methods

Fasting blood samples were obtained at baseline and at the end of the treatment period. Except for standard biochemistry and blood-cell analyses, serum samples were stored at −80°C and analyzed at the end of the study. Total cholesterol, triglycerides, and HDL-cholesterol [after precipitation of apolipoprotein (apo) B–containing lipoproteins] were determined by standard enzymatic methods in an automatic analyzer DDPPII Hitachi (Roche, Roche, Basle, Switzerland), using specific reagents (Boehringer-Mannheim, Mannheim, Germany). LDL-cholesterol was calculated by using the Friedewald equation. ApoAI and apoB were determined by using turbidimetry. Concentrations of variables reflecting glucose control and kidney and liver function, i.e., fasting glucose, total bilirubin, aspartate aminotransferase, alanine transaminase, alkaline phosphatase, γ-glutamyl transpeptidase, and creatinine were determined on the automatic analyzer. Hematological variables (total and differential white blood cell count, red blood cell count, hemoglobin concentration, hematocrit, mean corpuscular volume, and platelet count and volume) were determined on a Coulter counter.

Non-cholesterol sterols and high sensitivity C-reactive protein (CRP) were determined in frozen samples of whole serum. Plant sterols (campesterol and sitosterol)
and the cholesterol precursor lathosterol were analyzed by gas chromatography as previously described [19]. Briefly, epicoprostanol (2 μg) was added to serum (0.1 ml) as internal standard. After alkaline hydrolysis, extraction, and derivatization to trimethylsilyl ethers, the sterols were quantified by gas chromatography on a 30 m nonpolar capillary column (TRB-Esterol; Teknokroma, Barcelona, Spain) with a Perkin-Elmer GC Autosystem (Perkin-Elmer, Norwalk, CT, USA). Plant sterol and precursors concentrations are expressed as ratios to cholesterol (μmol/mmol cholesterol). Inter- and intra-assay CVs were 5.0% and 3.2% for lathosterol, 1.9% and 1.6% for campesterol, and 2.0% and 1.8% for sitosterol, respectively. CRP was determined by turbidimetry. The intra-assay coefficient of variation for CRP was 3.1%.

The number of CD4 T lymphocytes was measured by flow cytometry. Plasma HIV-1 RNA was measured by a PCR assay (Amplicor HIV Monitor, Roche Diagnostics Systems, Branchburg, New Jersey, USA; lower limit of detection 50 copies/mL).

### Statistical analyses

The primary efficacy variable was the change in serum LDL-cholesterol. Key secondary variables were changes in other lipids, non-cholesterol sterols, and CRP. Variables were described as medians and interquartile ranges. Outlier values of CRP (1.5 times the interquartile range above the median) were excluded from the analysis of CRP response. A sample size of 15 evaluable patients was considered necessary to detect a decrease of at least 20% in LDL-cholesterol, according to previous data [20], with an 80% power and a significance level of 0.05, using a two-sided test. We used the Wilcoxon rank test for within-group comparisons and the Spearman’s rho test for correlation between continuous variables. Analyses were performed using SPSS software version 16.0.

### Results

#### Baseline characteristics

Fifteen patients (9 men and 6 women, mean age 53 years) were included and eligible for analysis. Eight

### Table 1: Baseline data and outcome variables in 15 patients treated with ezetimibe for 8 weeks

| Variables                      | Baseline  | Treatment | % change | P*     |
|--------------------------------|-----------|-----------|----------|--------|
| Dietary assessment             |           |           |          |        |
| Total calories (kJ/d)          | 8037 [6728–9033] | 7657 [6841–11167] | -4.7% | .55    |
| Total fat (g/d)                | 93 [76–105] | 86 [83–115] | -7.5% | .53    |
| Saturated fatty acids (g/d)    | 26 [17–31] | 24 [19–32] | -7.7% | .94    |
| Cholesterol (mg/d)             | 254 [223–340] | 294 [247–346] | 15.7 | .81    |
| Phytosterols (mg/d)            | 184 [141–211] | 156 [129–193] | -15.2% | .09    |
| Body weight (kg)               | 73.0 [61.2–80.1] | 73.1 [63.9–80.8] | 0.1% | 1      |
| Waist circumference (cm)       | 92.5 [85.7–96] | 95.0 [88–100] | 2.7% | .55    |
| Lipids and apos                |           |           |          |        |
| Total cholesterol (mmol/L)     | 5.87 [5.46-6.54] | 5.2 [4.89-5.61] | -11.4% | .002   |
| LDL-cholesterol (mmol/L)       | 3.93 [3.46-4.27] | 3.13 [2.95-3.44] | -20.4% | .003   |
| nonHDL-cholesterol (mmol/L)    | 4.63 [4.29-5.30] | 4.01 [3.59-4.42] | -13.4% | .002   |
| HDL-cholesterol (mmol/L)       | 1.21 [1.11-1.47] | 1.19 [1.03-1.34] | -2.1% | .11    |
| Triglycerides (mmol/L)         | 1.64 [1.15-2.04] | 1.42 [1.15-2.29] | -13.1% | .46    |
| Apo A1 (g/L)                   | 1.47 [1.39-1.53] | 1.54 [1.44-1.59] | 4.7% | 1      |
| Apo B (g/L)                    | 1.21 [1.09-1.42] | 1.10 [0.95-1.24] | -9.1% | .02    |
| C-reactive protein (mg/L)      | 1.2 [0.4-1.6] | 0.6 [0.5-3.5] | -50% | .61    |
| Plasma viral load (copies/mL)  | 49 [49–49] | 49 [49–49] | 0% | .65    |
| CD4 cell count (cells/μL)      | 503 [353–802] | 499 [323–794] | -0.8% | .65    |
| Lathosterol (μmol/L)           | 7.08 [5.19-9.43] | 9.97 [6.68-12.67] | 40.9% | .015   |
| Lathosterol/cholesterol        | 1.26 [0.84-1.54] | 1.93 [1.37-2.40] | 53.2% | .005   |
| Campesterol (μmol/L)           | 27.78 [20.22-38.95] | 14.78 [10.72-18.51] | -46.8% | .001   |
| Campesterol/cholesterol        | 4.65 [3.23-6.36] | 2.62 [1.98-3.53] | -43.6% | .001   |
| Sitosterol (μmol/L)            | 22.96 [20.34-33.25] | 14.77 [10.96-19.52] | -35.7% | .001   |
| Sitosterol/cholesterol         | 4.46 [3.70-6.09] | 2.59 [2.17-3.76] | -41.9% | .001   |

Results are expressed as medians [IQR]. *Wilcoxon Rank test.
Efficacy

After 8 weeks of ezetimibe treatment, significant changes from baseline were observed for total cholesterol (−0.67 mmol/L; \( p = .002 \)), LDL-cholesterol (−0.80 mmol/L; \( p = .003 \)), non-HDL-cholesterol (−0.62 mmol/L; \( p = .002 \)) and apoB (−0.11 g/L; \( p = .021 \)). No significant changes were observed for HDL-cholesterol, triglycerides, apoA1 or CRP (Table 1). Total cholesterol and LDL-cholesterol responses were consistent in most patients (Figure 1).

Treatment with ezetimibe was associated with a reduction in plasma campesterol and sitosterol concentrations in every participant, which confirms participants’ compliance with the study drug. Similar results were observed for their ratios to cholesterol. Conversely, plasma lathosterol increased in most treated subjects (Table 1, Figure 1).

Concerning safety, CD4 cell count and plasma HIV-1 RNA remained unchanged. No changes in routine biochemistry or hematologic parameters were observed.

Relationship between markers of cholesterol metabolism and response to treatment

Baseline campesterol- and sitosterol-to-cholesterol ratios (as markers of absorption) and the lathosterol-to-cholesterol ratio (as a marker of synthesis) were not associated with the cholesterol lowering response to ezetimibe, as judged by the lack of correlation between these variables and changes in LDL-cholesterol after treatment. No correlation was observed either between baseline lipid levels and these markers.

Baseline campesterol- and sitosterol-to-cholesterol ratios were highly correlated between them (\( r = .932; p < .001 \)). Although lathosterol-to-cholesterol ratio increased as expected in response to cholesterol absorption inhibition, the changes were unrelated to those of either campesterol or sitosterol. Changes in CRP did not correlate with changes in plasma lipids or non-cholesterol sterols.

Previous antiretroviral exposure (total cART or sub-families: TA- and non-TA-RTI, PI, NNRTI) did not show any correlation with markers of cholesterol absorption or synthesis. No association existed between antiretroviral exposure and baseline lipid levels either.

Discussion

In this study we confirmed that 8 weeks of ezetimibe monotherapy was effective in reducing total and LDL-cholesterol in HIV patients receiving boosted-PI containing ART. The reduction in LDL-cholesterol levels (−20.4%) was
in the expected range of responses reported in studies of ezetimibe monotherapy in the general population with dyslipidemia (−16% to −20%) [15-17], as well as in HIV-infected patients [21]. According to our data, seropositive patients receiving boosted-PI do not necessarily have a weaker response to ezetimibe, as suggested by Wohl et al. [20]. These authors found a poor response to ezetimibe (−5.3% LDL-cholesterol reduction) in HIV patients on triple therapy, but their mean baseline LDL-cholesterol (3.31 mmol/L) was lower than that in our population, which could account, at least in part, for the differences observed.

However, despite its efficacy in reducing serum cholesterol levels, the effectiveness of ezetimibe in reducing major cardiovascular events is yet to be proven. There is an ongoing clinical trial (IMPROVE-IT; ClinicalTrials.gov identifier NCT00202878) addressing this issue.

In our study ezetimibe resulted in a reduction in cholesterol absorption markers and an increase in cholesterol synthesis markers, which were in the range of the changes reported in non-HIV dyslipidemic subjects [15,17,18], suggesting that PI-containing ART has no major effect on cholesterol absorption or synthesis. However, the level of cholesterol absorption does not appear to be a major determinant of the responsiveness to ezetimibe, as shown by the lack of correlation between cholesterol absorption or synthesis markers and baseline lipid levels or their response to therapy. Other studies in non-HIV hypercholesterolemic subjects have produced similar results [22,23]. In one study, only a weak inverse correlation (r = −0.17) was found between baseline campesterol-to-lathosterol ratio and the response to ezetimibe [18]. In our study, neither baseline sitosterol- nor campesterol-to-lathosterol ratios correlated with response to therapy (data not shown). It is possible that factors downstream the primary site of action of ezetimibe could be major determinants of response.

In our study CRP decreased non-significantly after ezetimibe treatment. The great intra- and inter-individual variability observed with this marker makes it difficult to detect changes, at least in small studies. In a meta-analysis assessing the contribution of LDL-dependent effects of cholesterol-lowering therapies to changes in CRP, most of the CRP reduction was related to LDL changes [24]. As noted above, the small sample size is one limitation of our study, particularly for secondary outcomes. However, the study population was quite homogeneous for antiretroviral therapy and viral control, ruling out any potential influence of antiretroviral changes or uncontrolled HIV replication on the results.

Conclusions
The pharmacological inhibition of cholesterol absorption by ezetimibe is followed by a compensatory increase in cholesterol synthesis. The level of cholesterol absorption or synthesis prior to therapy does not appear to be a major determinant of the responsiveness to ezetimibe. Our findings in HIV patients receiving ronavir-boosted PI-containing therapy are similar to those reported in non-HIV hypercholesterolemic subjects, suggesting that therapy with protease inhibitors by itself does not substantially affect cholesterol homeostasis.

Abbreviations
ART: Antiretroviral therapy; cART: Combination ART; CRP: C-reactive protein; NPC1L1: Niemann-Pick C1-Like 1; PI: Protease inhibitors; RTI: Reverse Transcriptase Inhibitors; SREBP: Sterol regulatory element-binding protein; TA: Thymidine analogues.

Competing interests
The authors declare that they have no competing interests. The study drug ezetimibe was generously supplied by Merck Sharp & Dohme (MSD), Spain. MSD had no role in study design, data collection, analysis, and interpretation, or writing of the report.

Authors’ contributions
PL participated in study design, data monitoring, data analysis, and writing of the manuscript. EM participated in study design, recruitment, data monitoring, data analysis, and writing of the manuscript. ML participated in recruitment and data monitoring. MC carried out laboratory analysis of non-cholesterol esterols and CRP. JT and AP: carried out dietary counselling and analysis of dietary data. MF: participated in writing of the manuscript. ER participated in design, data analysis, writing and revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
Emili Corbella provided expert assistance with statistical analyses. CIBERobn is an initiative of ISCIII. The study was supported in part by grant FIS PS09/01292, ISCIII, Spain.

Author details
1 Endocrinology and Nutrition Service, Hospital Clinic, Universitat de Barcelona, Villarroel 170, Barcelona 08036, Spain. 2 Infectious Diseases Unit, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, Villarroel 170, Barcelona 08036, Spain. 3 Lipid Clinic, IDIBAPS, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain. 4 Lipid Clinic, Clinical Research Unit, Clínic, Villarroel 170, Barcelona 08036, Spain. 5 Fundació Clinic per la Recerca Biomèdica, Hospital Clinic, Villarroel 170, Barcelona 08036, Spain.

Received: 3 July 2014 Accepted: 2 September 2014
Published: 11 September 2014

References
1. Carr A, Samaras KA, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093–99.
2. Friis-Møller N, Sabin CA, Weber R, Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993–2003.
3. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontes E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723–1735.
4. Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD. DAD study group. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 2003, 17:1179–93.
5. Baker JV, Henry WK, Neaton JD. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paradigms. Curr Opin HIV AIDS 2009, 4:176–182.
6. The EACS executive committee. Guidelines. Prevention and management of noninfectious co-morbidities in HIV. [http://www.eacsociety.org/Guidelines.aspx]
7. Ray GM: Antiretroviral and Statin Drug-Drug Interactions. Cardiol Rev 2009, 17:44–47.
8. Silverberg MJ, Leyden W, Hurley L, Go AS, Quessenberry CP Jr, Klein D, Hobberg MA: Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009, 150:301–313.
9. Van Heek M, Davis H: Pharmacology of ezetimibe. Eur J Heart 2002, 4(suppl):J3–J8.
10. Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003, 42:81–92.
11. Miettinen TA, Tikitik RS, Kesäniemi YA: Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990, 131:20–31.
12. Matthan NR, Reaín-Sarajz M, Lichtenstein AH, Ausman LM, Jones PJ: Deuterium uptakes and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hypercholesterolemic women. Lipids 2000, 35:1037–44.
13. Von Bergmann K, Sudhop T, Lüthohann D: Cholesterol and plant sterol absorption: recent insights. Am J Cardiol 2005, 96(suppl):10D–14D.
14. Sudhop T, Lüthohann D, von Bergmann K: Sterol transporters: targets of natural sterols and new lipid lowering drugs. Pharmacol Ther 2005, 105:333–41.
15. Sudhop T, Lüthohann D, Kodai A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002, 106:1943–48.
16. Duvojne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP, Ezetimibe Study Group: Efficacy of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1092–1097.
17. Hiramitsu S, Ishiguro Y, Matsuyama H, Yarnada K, Kato K, Noba M, Uemura A, Yoshida S, Matsubara Y, Kani A, Hasegawa K, Hishida H, Ozaki Y: The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J Atheroscler Thromb 2010, 17:106–114.
18. Assmann G, Kanneberg F, Ramey DR, Muslinder TA, Gutkin SW, Veltri EP: Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin 2008, 24:249–259.
19. Escurció V, Cofán M, Moreno-Flías C, Larrañaga N, Martínez C, Navao C, Rodríguez L, González CA, Corella D, Ros E: Phytosterol plasma concentrations and coronary heart disease in the prospective Spanish EPIC population study. J Lipid Res 2010, 51:618–624.
20. Wohl DA, Waters D, Simpson RJ Jr, Richard S, Schnell A, Napravnik S, Keys J, Eron JJ Jr, Hsue P: Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008, 47:1105–8.
21. Coll B, Aragonés G, Parra S, Alonso-Villaverde C, Marana L: Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006, 20:1675–7.
22. Lakoski SG, Xu F, Vega GL, Grundy SM, Chandnali M, Lam C, Lowe RS, Stepanavage ME, Muslinder TA, Cohen JC, Hobbs HH: Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab 2010, 95:800–809.
23. Jakuli J, Vissers MN, Groen AK, Hutten BA, Lutjohann D, Veltri EP, Kastelein JJ: Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J Lipid Res 2010, 51:65–75.
24. Kinlay S: Low-density lipoprotein-dependent and –independent effects of cholesterol-lowering therapies on C-reactive protein. J Am Coll Cardiol 2007, 49:2003–2009.

doi:10.1186/1471-2334-14-497
Cite this article as: Leyes et al.: Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial. BMC Infectious Diseases 2014 14:497.